Short-Term Metformin Protects Against Glucocorticoid-Induced Toxicity in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
Metformin prevents GC-induced insulin resistance and reduces markers of dyslipidemia, myopathy, and, possibly, bone resorption through AMPK-dependent and -independent pathways.
Authors
- Adhideb Ghosh (ORCID: https://orcid.org/0000-0002-5160-4571)
- Christine S. Zuern (ORCID: https://orcid.org/0000-0001-6625-284X)
- Christian Wolfrum (ORCID: https://orcid.org/0000-0002-3862-6805)
- Caspar Joyce Peterson (ORCID: https://orcid.org/0000-0002-6017-1712)
- Alaa Othman (ORCID: https://orcid.org/0000-0002-0092-5594)
- Vasco Iten
- Eleonora Seelig (ORCID: https://orcid.org/0000-0002-7092-1986)
- Michael Kühne (ORCID: https://orcid.org/0000-0002-2937-3711)
- Patricia Arroyo Tardio
- Isabel Reinisch (ORCID: https://orcid.org/0000-0002-3587-4635)
- Susanne Thierry
- Tarik Delko (ORCID: https://orcid.org/0000-0003-4868-6665)
- Nicola Zamboni (ORCID: https://orcid.org/0000-0003-1271-1021)
- Stéphanie Pfammatter
- Christian Meier (ORCID: https://orcid.org/0000-0003-4030-0350)
- Michael Epstein
Institutions
- University Hospital of Basel (CH)
- ETH Zurich (CH)
- Kantonsspital Baselland (CH)
- Hirslanden Klinik St. Anna (CH)
- St. Claraspital (CH)
- Biostatistical Consulting (United States) (US)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-02-03
- DOI
- https://doi.org/10.2337/dc24-2039
- Citations
- 2
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- National Science Foundation
- Novartis Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Novartis Stiftung für Medizinisch-Biologische Forschung